RT Journal Article
T1 Statins in Non-alcoholic Steatohepatitis.
A1 Torres-Peña, Jose D
A1 Martín-Piedra, Laura
A1 Fuentes-Jiménez, Francisco
K1 NASH
K1 aminotransferase
K1 cardiovascular disease
K1 liver
K1 statins
AB Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.
SN 2297-055X
YR 2021
FD 2021-11-24
LK https://hdl.handle.net/10668/25858
UL https://hdl.handle.net/10668/25858
LA en
DS RISalud
RD Apr 5, 2025